GC-509

N/A

Report date: 2024/11/13 15:02:13

Base Information

Drug NameGC-509
Drug Alias NameGC-509GC509
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT-cell antigen CD7 inhibitors
TargetsT-cell antigen CD7
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesGracell Biotechnologies (Shanghai) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGracell Biotechnologies (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A